NCT04356989

Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function

Xarelto® for the Prevention of Stroke and Noncentral Nervous Systemic Embolism in Non-valvular Atrial Fibrillation With REnal Impairment in Taiwanese Population.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 493 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

In this study researchers want to learn more about on the safety of the drug Xarelto. The study will enroll patients for whom the treating doctor are prescribing Xarelto for the prevention of brain attack or the prevention of blockage of an artery in the non-central nervous system. Only patients suffering from decreased renal function and irregular heart beat will be considered. The study plans to include 500 Taiwanese adult male and female patients with the age above 20 years. Patients will be followed up based on routine medical practice over a period of 12 months and information on their well-being and any medical events will collected.

Conditions

• Non-valvular Atrial Fibrillation (NVAF)

Interventions

Type	Name	Description
DRUG	Rivaroxaban (Xarelto, BAY59-7939)	The adminstration dose is decided by the attending physician in advance based on the patients' CrCl and in compliance with local market authorization of rivaroxaban.

Timeline

• Start date: 2020-05-13
• Primary completion: 2022-11-15
• Completion: 2023-01-16
• First posted: 2020-04-22
• Last updated: 2023-12-28

Locations

1 site across 1 country: Taiwan